Do patients have to choose between ejaculation and miction? A systematic review about ejaculation preservation technics for benign prostatic obstruction surgical treatment.


Journal

World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716

Informations de publication

Date de publication:
Feb 2019
Historique:
received: 25 04 2018
accepted: 04 06 2018
pubmed: 4 7 2018
medline: 29 5 2019
entrez: 4 7 2018
Statut: ppublish

Résumé

Ejaculatory dysfunction is the most common side effect related to surgical treatment of benign prostatic obstruction (BPO). Nowadays, modified surgical techniques and non-ablative techniques have emerged with the aim of preserving antegrade ejaculation. Our objective was to conduce a systematic review of the literature regarding efficacy on ejaculatory preservation of modified endoscopic surgical techniques, and mini-invasive non-ablatives techniques for BPO management. A systematic review of the literature was carried out on the PubMed database using the following MESH terms: "Prostatic Hyperplasia/surgery" and "Ejaculation", in combination with the following keywords: "ejaculation preservation", "photoselective vaporization of the prostate", "photoselective vapo-enucleation of the prostate", "holmium laser enucleation of the prostate", "thulium laser", "prostatic artery embolization", "urolift", "rezum", and "aquablation". The ejaculation preservation rate of modified-TURP ranged from 66 to 91%. The ejaculation preservation rate of modified-prostate photo-vaporization ranged from 87 to 96%. The only high level of evidence studies available compared prostatic urethral lift (PUL) and aquablation versus regular TURP in prospective randomized-controlled trials. The ejaculation preservation rate of either PUL or aquablation compared to regular TURP was 100 and 90 versus 34%, respectively. Non-ablative therapies and modified endoscopic surgical techniques seemed to be reasonable options for patients eager to preserve their ejaculatory functions.

Identifiants

pubmed: 29967947
doi: 10.1007/s00345-018-2368-6
pii: 10.1007/s00345-018-2368-6
doi:

Substances chimiques

Steam 0

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

299-308

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Références

BJU Int. 1999 Feb;83(3):227-37
pubmed: 10233485
J Urol. 2001 May;165(5):1526-32
pubmed: 11342911
BMJ. 2002 May 4;324(7345):1059-61
pubmed: 11991908
Eur Urol. 2003 Dec;44(6):637-49
pubmed: 14644114
J Urol. 2004 Sep;172(3):1012-6
pubmed: 15311026
Eur Urol. 2006 Jun;49(6):970-8; discussion 978
pubmed: 16481092
Urology. 2007 May;69(5):805-9
pubmed: 17482908
Eur Urol. 2007 Nov;52(5):1456-63
pubmed: 17499427
Eur Urol. 2008 Feb;53(2):382-89
pubmed: 17566639
Urol Int. 2008;80(1):26-30
pubmed: 18204229
Prostate Cancer Prostatic Dis. 2009;12(3):277-80
pubmed: 19322136
World J Urol. 2010 Feb;28(1):23-32
pubmed: 20033744
BJU Int. 2010 Nov;106(9):1339-43
pubmed: 20477825
J Sex Med. 2010 Aug;7(8):2825-30
pubmed: 20487234
Urol Int. 2012;88(2):165-9
pubmed: 22237486
Prog Urol. 2012 Dec;22(16):977-88
pubmed: 23178093
Eur Urol. 2013 Jul;64(1):118-40
pubmed: 23541338
J Endourol. 2014 Jan;28(1):84-9
pubmed: 23952037
Radiology. 2014 Mar;270(3):920-8
pubmed: 24475799
Rev Med Liege. 2013 Dec;68(12):644-9
pubmed: 24564030
Int J Impot Res. 2015 Jan-Feb;27(1):20-4
pubmed: 25007827
BJU Int. 2015 Feb;115(2):186-7
pubmed: 25046575
J Endourol. 2015 Mar;29(3):332-9
pubmed: 25133981
Eur Urol. 2015 Jun;67(6):1099-1109
pubmed: 25613154
Urol Int. 1985;40(1):3-4
pubmed: 2579496
Urology. 2015 Jul;86(1):122-7
pubmed: 25987496
Can J Urol. 2015 Jun;22(3):7772-82
pubmed: 26068624
Int J Urol. 2016 Jan;23(1):22-35
pubmed: 26177667
Urology. 2015 Nov;86(5):1042-7
pubmed: 26216644
Eur Urol. 2016 Jan;69(1):94-102
pubmed: 26283011
BJU Int. 2016 Jun;117(6):923-9
pubmed: 26477826
Cardiovasc Intervent Radiol. 2016 Jan;39(1):44-52
pubmed: 26506952
Cardiovasc Intervent Radiol. 2016 Mar;39(3):367-75
pubmed: 26702619
J Vasc Interv Radiol. 2016 May;27(5):700-8
pubmed: 27019980
Urology. 2017 Jan;99:142-147
pubmed: 27725232
BJU Int. 2017 May;119(5):767-775
pubmed: 27862831
J Urol. 2017 Jun;197(6):1507-1516
pubmed: 27993667
Cardiovasc Intervent Radiol. 2017 May;40(5):655-663
pubmed: 28032133
J Urol. 2017 Jun;197(6):1565-1572
pubmed: 28111300
Can J Urol. 2017 Jun;24(3):8802-8813
pubmed: 28646935
Int Urol Nephrol. 2017 Oct;49(10):1741-1749
pubmed: 28780626
Urology. 2018 Jan;111:1-9
pubmed: 29122620
J Urol. 2018 May;199(5):1252-1261
pubmed: 29360529
Br J Urol. 1985 Apr;57(2):164-7
pubmed: 4039208
Br J Urol. 1994 Apr;73(4):442-8
pubmed: 8199835
J Urol. 1994 Jan;151(1):54-61
pubmed: 8254833
Br J Urol. 1998 Jun;81(6):830-3
pubmed: 9666766

Auteurs

Souhil Lebdai (S)

Urology Department, University Hospital of Angers, CHU Angers, 4 rue Larrey, 49933, Angers Cedex 9, France. souhil.lebddai@gmail.com.

Armand Chevrot (A)

Urology Department, University Hospital of Nimes, 30900, Nîmes, France.

Steeve Doizi (S)

Urology Department, Hôpital Européen Georges Pompidou, Paris, France.

Benjamin Pradere (B)

Urology Department, University Hospital of Tours, Tours, France.

Nicolas Barry Delongchamps (NB)

Urology Department, University Hospital of Cochin, 75014, Paris, France.

Amine Benchikh (A)

Urology Department, Clinique les Martinets, Versailles, France.

Jean Nicolas Cornu (JN)

Urology Department, University Hospital of Rouen, Rouen, France.

Emmanuel Della Negra (E)

Urology Department, Hôpital des Côtes d'Armor, Saint Brieuc, France.

Marc Fourmarier (M)

Urology Department, Hospital of Aix en Provence, 13001, Aix en Provence, France.

Vincent Misraï (V)

Urology Department, Clinique Pasteur, Toulouse, France.

Pierre Etienne Theveniaud (PE)

Urology Department, Saint Joseph Hospital, Paris, France.

Aurélien Descazeaud (A)

Urology Department, University Hospital of Limoges, Limoges, France.

Grégoire Robert (G)

Urology Department, University Hospital of Bordeaux, Bordeaux, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH